πŸ‡ΊπŸ‡Έ FDA
Patent

US 10653704

Inhalable formulation

granted A61KA61K31/56A61K9/0075

Quick answer

US patent 10653704 (Inhalable formulation) held by Teva Branded Pharmaceutical Products R&D, Inc. expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Teva Branded Pharmaceutical Products R&D, Inc.
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/56, A61K9/0075, A61K9/008, A61K9/124